EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Complications in the treatment of CLL with purine analogues

G Juliusson

Hematology and Cell Therapy · 1997

DOI: 10.1007/pl00021052 ↗

At a glance

Übersichtsarbeit in Hematology and Cell Therapy, 1997. Written by G Juliusson. Institution: Department of Hematology, University Hospital, Linkoping, Sweden. Cited 6 times so far (Crossref).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The main complications from treatment of CLL with purine analogues are bone marrow depression resulting in cytopenia, immune suppression leading to infections, particularly opportunistic infections, and immune deregulation with autoimmune hemolytic anemia as the most common feature. These complications usually delay or even prevent further treatment, thus leading to a reduced clinical response. In order to achieve the greatest benefit from purine analogue therapy, it is important to be able to predict the risk of such complications, and to use a treatment strategy with optimal dose intensity, by prophylactic supportive care when required, and by early detection and adequate management of complications.

Subjects

MeSH terms (MEDLINE)

Anemia, Hemolytic, AutoimmuneHumansInfectionsLeukemia, Lymphocytic, Chronic, B-CellNeutropeniaPurine NucleosidesVidarabine

Substances

Purine NucleosidesVidarabinefludarabine

Authors and institutions

  • Department of Hematology, University Hospital, Linkoping, Sweden.

Cite

APA

Juliusson, G. (1997). Complications in the treatment of CLL with purine analogues. Hematology and Cell Therapy. https://doi.org/10.1007/pl00021052

Vancouver

Juliusson G. Complications in the treatment of CLL with purine analogues. Hematology and Cell Therapy. 1997. doi:10.1007/pl00021052

BibTeX
@article{Juliusson1997,
  author = {Juliusson, G},
  title = {Complications in the treatment of CLL with purine analogues},
  journal = {Hematology and Cell Therapy},
  year = {1997},
  doi = {10.1007/pl00021052}
}
Start for free →